Ziopharm Oncology reported $-21960000 in EBITDA for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Amgen AMGN:US $ 3228M 40M
Arena Pharmaceuticals ARNA:US $ -123.51M 19.9M
AstraZeneca AZN:LN 2784M 588M
Baxter International BAX:US $ 822M 124M
Biogen BIIB:US $ 991.8M 155.8M
Bristol Myers Squibb BMY:US $ 5712M 33M
Corcept Therapeutics CORT:US $ 36.5M 4.3M
Curis CRIS:US $ -10.01M 0.6M
Eleven Biotherapeutics EBIO:US $ 100.34M 125.71M
Gilead Sciences GILD:US $ 4370M 1605M
GlaxoSmithKline GSK:LN 3660M 1034M
Intercept Pharmaceuticals ICPT:US $ -5.41M 6.8M
Johnson & Johnson JNJ:US $ 8192M 2043M
Karyopharm Therapeutics KPTI:US $ -43626000 5.19M
Novartis NOVN:VX SF 4837M 65M
Pfizer PFE:US $ 10235M 2245M
Ptc Therapeutics PTCT:US $ -76.33M 7.18M
Regeneron Pharmaceuticals REGN:US $ 1920.4M 1497.9M
Sangamo Biosciences SGMO:US $ -45.88M 0.57M
Verastem VSTM:US $ -14.78M 1.1M
YTE INCY:US $ 262.16M 92.39M